Brontictuzumab

DB12737InvestigationalProtein Based Therapies

Brontictuzumab has been used in trials studying the treatment of Adenoid Cystic Carcinoma, Relapsed or Refractory Solid Tumors, and Relapsed or Refractory Lymphoid Malignancies.

Mechanism: Pharmacologically active on Neurogenic locus notch homolog protein 1
Curator reviewed
Also known as: OMP-52M51

Resolves to

Compound

UNIIUNY2TQA40ECAS1447814-75-6

Targets

P46531NOTCH1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Brontictuzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account